Canada approves pegfilgrastim biosimilar Nyvepria

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Canada approves pegfilgrastim biosimilar Nyvepria

Biosimilares/Novedades | Posted 02/07/2021 0 Post your comment

Canada’s drug regulator, Health Canada, has approved the filgrastim biosimilar Nyvepria (PF-06881894). The drug can be used to treat neutropenia (a lack of white blood cells) in cancer patients.

Nyvepria is a biosimilar of Amgen’s Neulasta (pegfilgrastim). Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim. It serves to stimulate the level of white blood cells (neutrophils). Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy.

Pfizer’s Nyvepria was approved on 18 January 2021 as a solution for subcutaneous injection at a dose of 6 mg/0.6 mL.

There are already three pegfilgrastim biosimilars approved in Canada. Apotex’s Lapelga was the first to be approved in April 2018, followed by Biocon/Mylan’s Fulphila in December 2018 and finally Sandoz’s Ziextenzo in April 2020 [1].

The approval of Nyvepria marks the second biosimilar from Pfizer to be approved in Canada. The company also has a filgrastim biosimilar, Nivestim, approved in the country [1].

Nyvepria also been approved in the US [2] and in Europe [3].

Related article
Biosimilars of pegfilgrastim

LATIN AMERICAN FORUM The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View this week’s headline article: La Epoetina biosimilar en Estados Unidos – obstáculos y recomendaciones Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de esta semana: La Epoetina biosimilar en Estados Unidos – obstáculos y recomendaciones Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 2]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Canada
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves pegfilgrastim biosimilar Nyvepria [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 2]. Available from: www.gabionline.net/Biosimilars/News/FDA-approves-pegfilgrastim-biosimilar-Nyvepria
3. GaBI Online - Generics and Biosimilars Initiative. EC approval for pegfilgrastim biosimilar Nyvepria [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 2]. Available from: www.gabionline.net/Biosimilars/News/EC-approval-for-pegfilgrastim-biosimilar-Nyvepria

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Health Canada